Prof. Dr. Ahmet BİLİCİ

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology , cilt.36, sa.5, ss.293-301, 2025 (SCI-Expanded, Scopus, TRDizin)

32. Hepatoselüler kanserli hastalarda lokal bölgesel tedaviler ve sorafenib kombinasyonun etkinlik ve güvenilirliği: tek merkez deneyimi

Muglu H., Sünger E., YÜCEL M. H., Mildanoğlu M. M., Delipoyraz E. E., J., et al.

Ege Tıp Dergisi , cilt.64, sa.1, ss.71-76, 2025 (TRDizin)

33. An Unusual Case of Metastatic Gastric Cancer Presenting with Right Heart Failure and Cardiac Metastasis

Engin Delipoyraz E., MILDANOĞLU M. M., SÜRÜL B., OLMUŞÇELİK O., ERKANLI K., BİLİCİ A.

Medicina (Lithuania) , cilt.61, sa.2, 2025 (SCI-Expanded, Scopus)

34. Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes.

Yıldiz A., BİLİCİ A., AÇIKGÖZ Ö., HAMDARD J., BASIM P., ÇAKIR T., et al.

Journal of chemotherapy (Florence, Italy) , cilt.37, sa.1, ss.60-68, 2025 (SCI-Expanded, Scopus)

35. Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience

Hamdard J., Bilici A., Sakin A., Kahraman S., Yasin A. I., Kalaci E., et al.

Journal of Chemotherapy , cilt.37, sa.3, ss.268-277, 2025 (SCI-Expanded, Scopus)

36. Sequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes

Ozbay M., Harputluoglu H., Karaca M., Tekin O., Sendur M., Kaplan M., et al.

CANCERS , cilt.16, sa.22, 2024 (SCI-Expanded, Scopus)

37. Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study

Karcı E., Bilici A., Bayram B., Celayir M., Ozyurt N., Oyan Uluç B., et al.

Cancers , cilt.16, sa.19, 2024 (SCI-Expanded, Scopus)

38. Total Neoadjuvant Therapy Versus Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: A Multi-Institutional Real-World Study

Şenocak Taşçı E., Mutlu A. U., Saylık O., ÖLMEZ Ö. F., BİLİCİ A., Sünger E., et al.

Cancers , cilt.16, sa.18, 2024 (SCI-Expanded, Scopus)

39. Is Clinical Risk Score a Useful Predictive Marker of Early Recurrence Among Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors?

OVEN B. B., ÖKTEN I. N., BİLİCİ A., YASİN A. I., KOCA S., YÜZÜGÜLLÜ E., et al.

Eurasian Journal of Medical Investigation , cilt.8, sa.2, ss.106-112, 2024 (TRDizin)

40. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer

Dent R., André F., Gonçalves A., Martin M., Schmid P., Schütz F., et al.

Annals of Oncology , cilt.35, sa.7, ss.630-642, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

41. Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study

Karadurmus N., Kaplan M., Sendur M., Urun Y., Demirci U., Karaca S., et al.

CURRENT MEDICAL RESEARCH AND OPINION , 2024 (SCI-Expanded, Scopus)

42. Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer

Kutlu Y., Cekin R., Göktaş Aydın S., Shbair A. T. M., Bilici A., Arici S., et al.

CURRENT PROBLEMS IN CANCER , cilt.50, 2024 (SCI-Expanded, Scopus)

43. Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study

KUTLU Y., Dae S. A., YILMAZ F., Erdem D., Sendur M. A. N., Akbas S., et al.

Cancers , cilt.16, sa.12, 2024 (SCI-Expanded, Scopus)

44. Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours-results from a Turkish multi-centre study

ÖLMEZ Ö. F., BİLİCİ A., ER Ö., BİŞGİN A., Sevinc A., Akman T., et al.

Japanese journal of clinical oncology , cilt.54, sa.5, ss.562-568, 2024 (SCI-Expanded, Scopus)

45. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data.

Göktaş Aydın S., Ölmez Ö. F., Selvi O., Geredeli C., Özden F., Bilici A., et al.

Journal of gastrointestinal cancer , cilt.55, sa.1, ss.227-236, 2024 (ESCI, Scopus)

46. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study

Guven D. C., Aykan M. B., MUĞLU H., BAYRAM E., Helvaci K., DURSUN B., et al.

Cancer Medicine , cilt.13, sa.1, 2024 (SCI-Expanded, Scopus)

47. Integrated FDG-PET/CT contribution over cross-sectional imaging in recurrence or progression of pancreaticobiliary neoplasms

Karaalioglu B., ÇAKIR T., KUTLU Y., ŞEKER M., BİLİCİ A.

Abdominal Radiology , cilt.49, sa.1, ss.131-140, 2024 (SCI-Expanded, Scopus)

48. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing

KÖSTEK O., Demirel A., Hacıoğlu M. B., TAŞTEKİN D., KARABULUT S., Gündogdu A., et al.

Journal of Chemotherapy , cilt.36, sa.7, ss.613-621, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

49. Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide

Goktas Aydin S., Kutlu Y., Muglu H., Aydin A., Acikgoz Ö., Hamdard J., et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , cilt.93, ss.71-78, 2024 (SCI-Expanded, Scopus)

50. THE IMPORTANCE OF CLINICAL AND LABORATORY PARAMETERS OF BONE MARROW METASTASIS IN PATIENTS WITH SOLID MALIGNANCY-SINGLE CENTER EXPERIENCE

Sadri S., J., Beköz H. S., Cakir A., ÖLMEZ Ö. F., Bilici A.

Karya Journal of Health Science , cilt.4, sa.3, ss.187-191, 2023 (TRDizin)

51. Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye.

Cicin I., Karadurmus N., Bilici A., Bahsi T., Sendur M. A., Demirci U., et al.

Future oncology (London, England) , 2023 (SCI-Expanded, Scopus)

52. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

Aydın S. G., Kavak E. E., Topcu A., Bayramgil A., Akgul F., Kahraman S., et al.

Biomolecules and Biomedicine , cilt.23, sa.6, ss.1089-1095, 2023 (Scopus)

53. Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer

GÖKTAŞ AYDIN S., BİLİCİ A., ÇALIŞ E., KUTLU Y., HAMDARD J., MUĞLU H., et al.

INTERNATIONAL IMMUNOPHARMACOLOGY , cilt.124, 2023 (SCI-Expanded, Scopus)

54. Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib

ÖLMEZ Ö. F., BİLİCİ A., Gursoy P., ÇUBUKÇU E., Sakin A., KORKMAZ T., et al.

Pulmonology , cilt.29, sa.6, ss.478-485, 2023 (Scopus) Sürdürülebilir Kalkınma

55. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study

Bilici A., Koca S., Karaagac M., Aydin S. G., Eraslan E., Kaplan M. A., et al.

Journal of Cancer Research and Clinical Oncology , cilt.149, sa.11, ss.8243-8253, 2023 (SCI-Expanded, Scopus)

56. The Efficacy And Safety of CDK 4/6 Inhibitors Plus Endocrine Therapy With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2- Negative Metastatic Breast Cancer Patients

acikgoz o., Göktaş Aydın S., Bilici A., Kutlu Y., Muglu H., Karcı E., et al.

ACTA ONCOLOGICA TURCICA , cilt.56, sa.2, ss.153-160, 2023 (TRDizin)

57. The Prognostic Utility of the Metastatic Lymph Node Ratio and the Number of Regional Lymph Nodes Removed from Patients with Small Bowel Adenocarcinomas

Aydin D., KEFELİ U., Ozcelik M., Erdem G. U., ŞENDUR M. A. N., Yildirim M. E., et al.

Medicina (Lithuania) , cilt.59, sa.8, 2023 (SCI-Expanded, Scopus)

58. Clinicopathological and Survival Characteristics of Mismatch Repair Status and PD-1 Expression in Serous Ovarian Cancer

Olmez F., Oglak S. C., Akgol S., ÖLMEZ Ö. F., BİLİCİ A., Akbayir O., et al.

Journal of the College of Physicians and Surgeons Pakistan , cilt.33, sa.6, ss.66-672, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

59. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy

Kutlu Y., Aydin S. G., Bilici A., Oven B. B., Ölmez Ö. F., Açıkgöz Ö., et al.

Medicine (United States) , cilt.102, sa.15, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

60. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study

BİLİCİ A., ÖLMEZ Ö. F., Kaplan M. A., Oksuzoglu B., Sezer A., Karadurmus N., et al.

ACTA ONCOLOGICA , cilt.62, sa.4, ss.381-390, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

61. The Optimal Treatment Approaches and Prognostic Factors in Elderly Patients with Advanced Stage Biliary Tract Tumors

AYDIN S., BİLİCİ A., ÖLMEZ F. Ö., ÇAKAN B., Yilmaz C., Aydın A., et al.

ACTA ONCOLOGICA TURCICA , cilt.56, sa.1, ss.81-89, 2023 (TRDizin)

62. SURVIVAL EFFECT OF PALLIATIVE RADIOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DEVELOPING OLIGO-PROGRESSION UNDER ANTIANDROGEN TREATMENT

Aydın S., Kutlu Y., Muglu H., Açıkgöz Ö., Aydın A., Bilici A., et al.

İstanbul Tıp Fakültesi Dergisi , cilt.86, sa.2, ss.117-122, 2023 (ESCI, TRDizin)

63. The Predictive Importance of Body Mass Index on Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer

Emirzeoglu L., Arici S., Sahin A. B., Ocak B., AK N., Ay S., et al.

Breast Care , cilt.18, sa.1, ss.42-48, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

64. Survival outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical therapy: a multicenter analysis

Acikgoz O., Bilici A., Tataroglu Ozyukseler D., Göktaş Aydın S., Selcukbiricik F., Rzazade R., et al.

Turkish Journal of Medical Sciences , cilt.53, sa.4, ss.949-961, 2023 (SCI-Expanded, Scopus, TRDizin)

65. Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer

Erol V. B., GÖKTAŞ AYDIN S., BİLİCİ A., ÇAKIR A., AÇIKGÖZ Ö., ÖLMEZ Ö. F., et al.

Journal of Chemotherapy , cilt.35, sa.7, ss.662-670, 2023 (SCI-Expanded, Scopus)

66. Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group

Gürbüz M., Kiliçkap S., BİLİCİ A., Karadurmuş N., Sezer A., ŞENDUR M. A. N., et al.

Medicine (United States) , cilt.101, sa.50, 2022 (SCI-Expanded, Scopus)

67. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

Gürbüz M., KUTLU Y., Akkuş E., KÖKSOY E. B., Köse N., Öven B. B., et al.

Journal of Cancer Research and Clinical Oncology , cilt.148, sa.12, ss.3547-3555, 2022 (SCI-Expanded, Scopus)

68. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group

Erol C., ŞENDUR M. A. N., Bilgetekin I., Garbioglu D. B., HAMDARD J., Akbas S., et al.

Journal of Cancer Research and Therapeutics , cilt.18, sa.9, ss.347-353, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

69. The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer

Aydin S. G., BİLİCİ A., ÖLMEZ Ö. F., Oven B. B., AÇIKGÖZ Ö., ÇAKIR T., et al.

Breast Care , cilt.17, sa.5, ss.470-479, 2022 (SCI-Expanded, Scopus)

70. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer.

GÖKTAŞ AYDIN S., Cakan Demirel B., BİLİCİ A., Topcu A., Aykan M. B., KAHRAMAN S., et al.

Current medical research and opinion , cilt.38, sa.10, ss.1751-1758, 2022 (SCI-Expanded, Scopus)

71. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

Hizal M., Bilgin B., Paksoy N., AÇIKGÖZ Ö., Sezer A., Gürbüz M., et al.

Journal of Cancer Research and Clinical Oncology , cilt.148, sa.6, ss.1501-1508, 2022 (SCI-Expanded, Scopus)

72. Treatment Management of Leptomeningeal and Brain Metastases as a First Reccurence Site in a Case with Germ Cell Testicular Tumor

GÖKTAŞ AYDIN S., BİLİCİ A., ÇAKIR A., ÖLMEZ Ö. F., CİLA A., ÜNAL D.

Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi , cilt.36, sa.1, ss.77-80, 2022 (TRDizin)

73. Efficacy and safety profile of COVID-19 vaccine in cancer patients: A prospective, multicenter cohort study

Yasin A. I., Aydin S. G., SÜMBÜL B., KORAL L., ŞİMŞEK M., Geredeli Ç., et al.

Future Oncology , cilt.18, sa.10, ss.1235-1244, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

74. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study

BİLİCİ A., Uysal M., Menekse S., Akin S., Yildiz F., Turan M., et al.

Cancer Investigation , cilt.40, sa.2, ss.199-209, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

75. The Impact of Hybrid Capture-Based Comprehensive Genomic Profiling on Treatment Strategies in Patients with Solid Tumors

Dişel U., Köse F., BİLİCİ A., ÖZGÜROĞLU M., Sağlam S., ŞEKER M., et al.

Journal of Oncological Science , cilt.8, sa.2, ss.87-93, 2022 (Scopus, TRDizin)

76. FACTORS PREDICTING RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED GASTRIC CANCER LOKAL İLERİ MİDE KANSERİNDE NEOADJUVAN KEMOTERAPİYE YANITI ÖNGÖREN FAKTÖRLER

Yildirim E., Bektaş S., GÖKTAŞ AYDIN S., Er A. M., Yanik I., Gümüşkaya P. Ö., et al.

Istanbul Tip Fakultesi Dergisi , cilt.85, sa.1, ss.41-50, 2022 (Scopus, TRDizin) Sürdürülebilir Kalkınma

77. Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer

İLHAN Y., TATLI A. M., Teker F., Onder A. H., Kose F., Geredeli C., et al.

International Journal of Gynecological Cancer , cilt.32, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

78. Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer

AÇIKGÖZ Ö., Cakan B., Demir T., BİLİCİ A., Oven B. B., HAMDARD J., et al.

Medicine (United States) , cilt.100, sa.44, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

79. Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck

SEZGİN GÖKSU S., TATLI A. M., Geredeli Ç., Atcı M., Besen A. A., Mertsoylu H., et al.

Cancer Chemotherapy and Pharmacology , cilt.88, sa.5, ss.805-812, 2021 (SCI-Expanded, Scopus)

80. Comparison of response and survival of first-line crizotinib therapy according to EML-4 ALK fusion variants in advanced non-small cell lung cancer patients: A Turkish Oncology Group study

TATLI A. M., Yumuk P. F., Oz B., BİLİCİ A., Gursoy P., Goker E., et al.

Journal of B.U.ON. , cilt.26, sa.6, ss.2457-2464, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

81. Merkel cell carcinoma in Turkey: A multicentric study

Yildiz F., Demirci U., Kucukarda A., BÜYÜKŞİMŞEK M., Sakalar T., Topcu T., et al.

Journal of Cancer Research and Therapeutics , cilt.17, sa.6, ss.1525-1529, 2021 (SCI-Expanded, Scopus)

82. The Effect of Cognitive Functions After Chemotherapy on Activity Performance and Social Participation in Breast Cancer Patients Meme Kanserli Hastalarda Kemoterapi Sonrası Bilişsel Fonksiyonların Aktivite Performansı ve Aktivite Katılım Üzerine Olan Etkisi

Akdemir G., Ünsal E., TARAKCI D., BİLİCİ A., Ölmez F. Ö., YILDIZ Ö.

Archives of Health Science and Research , cilt.8, sa.3, ss.189-195, 2021 (Scopus, TRDizin) Sürdürülebilir Kalkınma

83. Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey

Cakan B., AÇIKGÖZ Ö., BİLİCİ A., Demir T., Oven B. B., HAMDARD J., et al.

Journal of B.U.ON. , cilt.26, sa.5, ss.1908-1917, 2021 (SCI-Expanded, Scopus)

84. The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry Study

Soran A., Dogan L., Isik A., Ozbas S., Trabulus D. C., Demirci U., et al.

Annals of Surgical Oncology , cilt.28, sa.9, ss.5048-5057, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

85. Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-Small Cell Lung Cancer

AYDIN S. G., AÇIKGÖZ Ö., KUTLU Y., BİLİCİ A., HAMDARD J., ÖLMEZ Ö. F., et al.

ACTA ONCOLOGICA TURCICA , cilt.54, sa.3, ss.281-290, 2021 (TRDizin)

86. Triple-negative breast cancer presented with metastasis to the heart as first sign of recurrence

BAYRAMGİL A., BİLİCİ A., HAMDARD J., AÇIKGÖZ Ö., ŞEKER M., KILIÇASLAN F., et al.

Breast Journal , cilt.27, sa.1, ss.56-57, 2021 (SCI-Expanded, Scopus)

87. The conversion of RAS status in metastatic colorectal cancer patients after first-line biological agent treatment

Arici S., HAMDARD J., Sakin A., Sengiz Erhan S., Atci M. M., Cekin R., et al.

Colorectal Disease , cilt.23, sa.1, ss.206-212, 2021 (SCI-Expanded, Scopus)

88. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

Hacioglu M. B., Kostek O., KARABULUT S., TAŞTEKİN D., SEZGİN GÖKSU S., Alandag C., et al.

Journal of B.U.ON. , cilt.25, sa.4, ss.1897-1903, 2020 (SCI-Expanded, Scopus)

89. Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non-small-cell lung cancer

Selcukbiricik F., Ozdogan E., Dagel T., Tanju S., Erus S., Ertuglu L. A., et al.

Journal of Clinical Pharmacy and Therapeutics , cilt.45, sa.2, ss.303-308, 2020 (SCI-Expanded, Scopus)

90. Does primary tumor localization has prognostic importance in seminoma patients?: Turkish oncology Group study

Yildiz B., Kucukarda A., Gokyer A., Demiray A. G., PAYDAŞ S., Aral I. P., et al.

Journal of B.U.ON. , cilt.25, sa.2, ss.1130-1135, 2020 (SCI-Expanded, Scopus)

91. The potential prognostic role of peritumoral eosinophils within whole tumor-associated inflammatory cells and stromal histological characteristics in colorectal cancer

Ramadan S., Saka B., Yarikkaya E., BİLİCİ A., ÖNCEL M.

Polish Journal of Pathology , cilt.71, sa.3, ss.207-220, 2020 (SCI-Expanded, Scopus)

92. Prognostic Factors for Operated Gallbladder Cancer

Oven Ustaalioglu B. B., BİLİCİ A., Seker M., KEFELİ U., Aydin D., Celik S., et al.

Journal of Gastrointestinal Cancer , cilt.50, sa.3, ss.451-457, 2019 (Scopus) Sürdürülebilir Kalkınma

93. Anti-Ri-associated paraneoplastic neurological syndrome: Initial symptom of breast cancer with HER2 overexpression and treatment by dual HER2 blockade

ÖLMEZ Ö. F., Kinikoglu O., Yilmaz N. H., BİLİCİ A., ÇUBUKÇU E., ŞEKER M., et al.

Journal of Oncology Pharmacy Practice , cilt.25, sa.6, ss.1526-1530, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

94. The relationship between positron emission tomography-computed tomography imaging and histopathological features of thyroid incidentalomas detected during follow-up for primary malignancy

Oven B., Kilicoglu Z., BİLİCİ A., Tatoglu M., Canberk S., Tilki M., et al.

Journal of Cancer Research and Therapeutics , cilt.15, sa.3, ss.589-595, 2019 (SCI-Expanded, Scopus)

95. Prognostic Significance of Metastatic Lymph Node Ratio in Patients with pN3 Gastric Cancer Who Underwent Curative Gastrectomy

BİLİCİ A., Selcukbiricik F., ŞEKER M., Oven B. B., ÖLMEZ Ö. F., YILDIZ Ö., et al.

Oncology Research and Treatment , cilt.42, sa.4, ss.204-211, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

96. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes

Esin E., Oksuzoglu B., BİLİCİ A., ÇİÇİN İ., Kostek O., Kaplan M., et al.

Cancer Chemotherapy and Pharmacology , cilt.83, sa.1, ss.131-143, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

97. Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102

Hacioglu M. B., Kostek O., Kurt N., Kucukarda A., Gokyer A., Ustabasioglu F. E., et al.

Journal of B.U.ON. , cilt.24, sa.5, ss.2198-2204, 2019 (SCI-Expanded, Scopus)

98. Role of urotensin-2 in 5-fluorouracil-related arterial vasoconstriction in cancer patients

ŞEKER M., Isen H. C., Çevirme N., Aydln S., BİLİCİ A., Bulut H., et al.

Oncology Research and Treatment , cilt.41, sa.9, ss.545-549, 2018 (SCI-Expanded, Scopus)

99. Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy

YILDIZ İ., BİLİCİ A., Karadurmuş N., OZER L., Tural D., Kaplan M. A., et al.

Tumori , cilt.104, sa.6, ss.444-450, 2018 (SCI-Expanded, Scopus)

100. Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer

Ustaalioǧlu B. B. O., BİLİCİ A., Tilki M., Surmelioglu A., Erkol B., Figen M., et al.

Journal of Cancer Research and Therapeutics , cilt.14, sa.10, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

101. Evaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resection

Aydin D., Sendur M. A., KEFELİ U., Unal O. U., Tastekin D., Akyol M., et al.

Clinical Colorectal Cancer , cilt.16, sa.3, ss.220-227, 2017 (SCI-Expanded, Scopus)

102. Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors

Gumus M., BİLİCİ A., Odabas H., Ustaalioglu B. B. O., Kandemir N., Demirci U., et al.

World Journal of Urology , cilt.35, sa.7, ss.1103-1110, 2017 (SCI-Expanded, Scopus)

103. Brain Metastasis in a Patient with Malignant Melanoma: Melanotic Pattern

ARICI DÜZ Ö., YILMAZ N. H., BİRDAY E., ERTAN AKAN G., BİLİCİ A.

Türk Nöroloji Dergisi , cilt.23, sa.2, ss.79-80, 2017 (Scopus, TRDizin)

104. Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study

Bilir C., YILDIZ İ., BİLİCİ A., Ucar M., Berk V., Yıldız Y., et al.

Cancer Investigation , cilt.35, sa.4, ss.248-255, 2017 (SCI-Expanded, Scopus)

105. Correlation of Caveolin-1 Expression with Prognosis in Patients with Gastric Cancer after Gastrectomy

ŞEKER M., Aydin D., BİLİCİ A., Yavuzer D., Ozgun M. G., Ozcelik M., et al.

Oncology Research and Treatment , cilt.40, sa.4, ss.185-190, 2017 (SCI-Expanded, Scopus)

106. The clinicopathologic characteristics and prognostic factors of gastroesophageal junction tumors according to Siewert classification

Ustaalioǧlu B. B. Ö., Tilki M., Sürmelioǧlu A., BİLİCİ A., Gönen C., Ustaalioǧlu R., et al.

Turkish Journal of Surgery , cilt.33, sa.1, ss.18-24, 2017 (Scopus, TRDizin)

107. Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer

Selcukbiricik F., Kanbay M., Solak Y., BİLİCİ A., Kanıtez M., Balık E., et al.

Clinical and Translational Oncology , cilt.18, sa.11, ss.1082-1087, 2016 (SCI-Expanded, Scopus)

108. Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: Report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO)

Aydin D., Sendur M. A., KEFELİ U., Unal O. U., Tastekin D., Akyol M., et al.

Journal of B.U.ON. , cilt.21, sa.5, ss.1242-1249, 2016 (SCI-Expanded, Scopus)

109. Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy

Aydin D., BİLİCİ A., Kayahan S., Yavuzer D., Basar M., ALİUSTAOĞLU M.

Clinical and Translational Oncology , cilt.18, sa.6, ss.608-616, 2016 (SCI-Expanded, Scopus)

110. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases

Ulas A., BİLİCİ A., Durnali A., Tokluoglu S., Akinci S., SILAY K., et al.

Tumor Biology , cilt.37, sa.1, ss.1131-1140, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

111. The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival

Oven Ustaalioglu B., Balvan O., BİLİCİ A., Develi A., ALİUSTAOĞLU M., Vardar F., et al.

Clinical and Translational Oncology , cilt.17, sa.11, ss.895-902, 2015 (SCI-Expanded, Scopus)

112. Treatment preferences in stage IA and IB testicular seminoma: multicenter study of Anatolian Society of Medical Oncology

BİLİCİ A., Ozturk T., Turkmen E., Odabas H., Cihan S., Selcukbiricik F., et al.

World Journal of Urology , cilt.33, sa.10, ss.1613-1622, 2015 (SCI-Expanded, Scopus)

113. Prognostic markers for metastatic colon cancer patients undergoing multiple metastasectomies

Üstaalioʇlu B. B. O., Tilki M., Kílíçoʇlu Z. G., BİLİCİ A., Sürmelioʇlu A., Ustaalioʇlu R., et al.

Turkish Journal of Gastroenterology , cilt.26, sa.5, ss.386-391, 2015 (SCI-Expanded, Scopus, TRDizin)

114. Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy

Aydin D., BİLİCİ A., Yavuzer D., KEFELİ U., Tan A., Ercelep O., et al.

Clinical and Translational Oncology , cilt.17, sa.8, ss.604-611, 2015 (SCI-Expanded, Scopus)

115. Prognostic significance of the recurrence pattern and risk factors for recurrence in patients with proximal gastric cancer who underwent curative gastrectomy

BİLİCİ A., Selcukbiricik F.

Tumor Biology , cilt.36, sa.8, ss.6191-6199, 2015 (SCI-Expanded, Scopus)

116. The changing of serum vitamin B12 and homocysteine levels after gastrectomy in patients with gastric cancer: do they associate with clinicopathological factors?

BİLİCİ A., Sonkaya A., Ercan S., Ustaalioglu B. B. O., Seker M., ALİUSTAOĞLU M., et al.

Tumor Biology , cilt.36, sa.2, ss.823-828, 2015 (SCI-Expanded, Scopus)

117. Medication errors in chemotherapy preparation and administration: A survey conducted among oncology nurses in Turkey

Ulas A., Silay K., Akinci S., Dede D. S., AKINCI M. B., ŞENDUR M. A. N., et al.

Asian Pacific Journal of Cancer Prevention , cilt.16, sa.5, ss.1699-1705, 2015 (Scopus)

118. Clinical importance of discordance of hormone receptors and HER2/neu status after neoadjuvant chemotherapy in breast cancer

Ustaalioglu B. B. O., Vardar F. A., BİLİCİ A., Gurleyik G., Erkol B., Kefeli U., et al.

Journal of B.U.ON. , cilt.19, sa.4, ss.879-886, 2014 (SCI-Expanded, Scopus)

122. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2- negative advanced gastric cancer

BİLİCİ A., Selcukbiricik F., Demir N., Ustaalioglu B. B. O., Dikilitas M., YILDIZ Ö.

Asian Pacific Journal of Cancer Prevention , cilt.15, sa.20, ss.8661-8666, 2014 (SCI-Expanded, Scopus)

123. Prognostic factors for lymph node negative stage I and IIA non-small cell lung cancer: Multicenter experiences

Ustaalioglu B. B. O., Unal O. U., Turan N., BİLİCİ A., Kaya S., Eren T., et al.

Asian Pacific Journal of Cancer Prevention , cilt.14, sa.11, ss.6287-6292, 2013 (SCI-Expanded, Scopus)

124. Clinical and pathologic features of patients with rare ovarian tumors: Multi-center review of 167 patients by the anatolian society of medical oncology

BİLİCİ A., İNANÇ M., Ulas A., Akman T., Seker M., Babacan N. A., et al.

Asian Pacific Journal of Cancer Prevention , cilt.14, sa.11, ss.6493-6499, 2013 (SCI-Expanded, Scopus)

Yayınlar & Eserler